ArticleJournal of human genetics2014
Telomerase expression in amyotrophic lateral sclerosis (ALS) patients.
Article in Journal of human genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Telomerase activation in the treatment of aging or degenerative diseases: a systematic review.Molecular and cellular biochemistry · 2021Pooled it
- Telomerase Depletion Accelerates Ageing of the Zebrafish Brain.Aging cell · 2025Article
- Evaluation of the Telomere Length in Patients with Spinal Muscular Atrophy.International journal of molecular sciences · 2025Article
- Review
- T-cell lymphocytes' aging clock: telomeres, telomerase and aging.Biogerontology · 2024Review
- Impaired motor unit recovery and maintenance in a knock-in mouse model of ALS-associated Kif5a variant.Neurobiology of disease · 2023Article
- Telomerase reverse transcriptase and neurodegenerative diseases.Frontiers in immunology · 2023Review
- Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases.Antioxidants (Basel, Switzerland) · 2022Article
- Is Telomere Length Shortening a Risk Factor for Neurodegenerative Disorders?Dementia and neurocognitive disorders · 2022Review
- Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis.Translational neurodegeneration · 2022Article
- Genetically predicted telomere length and its relationship with neurodegenerative diseases and life expectancy.Computational and structural biotechnology journal · 2022Article
- Leukocyte telomere length and amyotrophic lateral sclerosis: a Mendelian randomization study.Orphanet journal of rare diseases · 2021Article
- A Non-Toxic Concentration of Telomerase Inhibitor BIBR1532 Fails to ReduceInternational journal of molecular sciences · 2021Article
- The Role of T Cell Senescence in Neurological Diseases and Its Regulation by Cellular Metabolism.Frontiers in immunology · 2021Review
- Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis.Scientific reports · 2020Article
- Decoding the relationship between ageing and amyotrophic lateral sclerosis: a cellular perspective.Brain : a journal of neurology · 2020Review
- Potential Preventive Strategies for Amyotrophic Lateral Sclerosis.Frontiers in neuroscience · 2020Review
- Telomere length is greater in ALS than in controls: a whole genome sequencing study.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2019Article
- Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases.Frontiers in molecular neuroscience · 2019Review
- Are There Modifiable Environmental Factors Related to Amyotrophic Lateral Sclerosis?Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomerase and telomeric complex have been linked to a variety of disease states related to neurological dysfunction. In amyotrophic lateral sclerosis (ALS) patients, telomerase activity, as human telomerase reverse transcriptase (hTERT) expression, has not been characterized yet. Here, for the first time, we characterized telomerase and related pathway in blood sample and spinal cord from ALS patients compared with healthy controls. We found that hTERT expression level was significantly lower in ALS patients and was correlated either to p53 mRNA expression or p21 expression, pointing out the hypothesis that telomerase inhibition could be a pathogenetic contributor to neurodegeneration in ALS. As a consequence of the reduced telomerase activity, we identified shorter telomeres in leukocytes from sporadic ALS patients compared with healthy control group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.